Evidence map›Paper›PMID 35174594›Full record

SynthesisBipolar disorders2022

Randomised controlled cognition trials in remitted patients with mood disorders published between 2015 and 2021: A systematic review by the International Society for Bipolar Disorders Targeting Cognition Task Force.

Kamilla W Miskowiak, Ida Seeberg, Mette B Jensen, Vicent Balanzá-Martínez, Caterina Del Mar Bonnin, Christopher R Bowie, Andre F Carvalho, Annemieke Dols, Katie Douglas, Peter Gallagher and 18 more

Open access · hybridAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Bipolar disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 3 pooled it
9.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 3 syntheses or guidelines pooled it, 67 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Bipolar disorder.Lancet (London, England) · 2025
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 20 institutions in 12 countries.

Kamilla W MiskowiakCopenhagen Affective Disorder Research Centre (CADIC), Psychiatric Centre Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.ORCID 0000-0003-2572-1384
Ida SeebergCopenhagen Affective Disorder Research Centre (CADIC), Psychiatric Centre Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.
Mette B JensenCopenhagen Affective Disorder Research Centre (CADIC), Psychiatric Centre Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.
Vicent Balanzá-MartínezTeaching Unit of Psychiatry and Psychological Medicine, Department of Medicine, University of Valencia, CIBERSAM, Valencia, Spain.
Caterina Del Mar BonninClinical Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain.
Christopher R BowieDepartment of Psychology, Queen's University, Kingston, Canada.ORCID 0000-0002-1983-8861
Andre F CarvalhoIMPACT Strategic Research Centre (Innovation in Mental and Physical Health and Clinical Treatment), Deakin University, Geelong, Vic., Australia.ORCID 0000-0002-2500-5671
Annemieke DolsDepartment of Old Age Psychiatry, GGZ in Geest, Amsterdam UMC, Location VUmc, Amsterdam Neuroscience, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands.ORCID 0000-0003-1964-0318
Katie DouglasDepartment of Psychological Medicine, University of Otago, Christchurch, New Zealand.ORCID 0000-0002-5344-2959
Peter GallagherTranslational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle-upon-Tyne, UK.
Gregor HaslerPsychiatry Research Unit, University of Fribourg, Fribourg, Switzerland.
Beny LaferBipolar Disorder Research Program, Institute of Psychiatry, Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil.ORCID 0000-0002-6132-9999
Kathryn E LewandowskiMcLean Hospital, Schizophrenia and Bipolar Disorder Program, Belmont, Massachusetts, USA.ORCID 0000-0003-1477-6187
Carlos López-JaramilloResearch Group in Psychiatry, Department of Psychiatry, Universidad de Antioquia, Medellín, Colombia.
Anabel Martinez-AranClinical Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain.
Roger S McIntyreMood Disorders Psychopharmacology Unit, Brain and Cognition Discovery Foundation, University of Toronto, Toronto, Canada.ORCID 0000-0003-4733-2523
Richard J PorterDepartment of Psychological Medicine, University of Otago, Christchurch, New Zealand.ORCID 0000-0002-8695-3966
Scot E PurdonDepartment of Psychiatry, University of Alberta, Edmonton, Canada.
Ayal SchafferDepartment of Psychiatry, University of Toronto.ORCID 0000-0001-6220-5042
Paul StokesDepartment of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.ORCID 0000-0002-2274-8330
Tomiki SumiyoshiDepartment of Preventive Intervention for Psychiatric Disorders, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, Japan.ORCID 0000-0001-9629-1671
Ivan J TorresDepartment of Psychiatry, University of British Columbia, Vancouver, Canada.
Tamsyn E Van RheenenMelbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne, Carlton, Australia.
Lakshmi N YathamDepartment of Psychiatry, University of British Columbia, Vancouver, Canada.
Allan H YoungDepartment of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Lars V KessingCopenhagen Affective Disorder Research Centre (CADIC), Psychiatric Centre Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.ORCID 0000-0001-9377-9436
Katherine E BurdickDepartment of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0003-4417-4988
Eduard VietaClinical Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain.ORCID 0000-0002-0548-0053
Centro de Investigación Biomédica en Red de Salud Mental · ESUniversity of Copenhagen · DKKing's College London · GBUniversity of British Columbia · CAUniversity of Otago · NZBrain and Cognition Discovery Foundation · CABrigham and Women's Hospital · USCopenhagen University Hospital · DKDeakin University · AUGGZ inGeest · NLHarvard University · USHospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo · BRNational Center of Neurology and Psychiatry · JPNewcastle University · GBQueen's University · CAThe University of Melbourne · AUUniversidad de Antioquia · COUniversitat de València · ESUniversity of Alberta · CAUniversity of Fribourg · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCognitive impairments are an emerging treatment target in mood disorders, but currently there are no evidence-based pro-cognitive treatments indicated for patients in remission. With this systematic review of randomised controlled trials (RCTs), the International Society for Bipolar Disorders (ISBD) Targeting Cognition Task force provides an update of the most promising treatments and methodological recommendations.

methodsThe review included RCTs of candidate pro-cognitive interventions in fully or partially remitted patients with major depressive disorder or bipolar disorder. We followed the procedures of the Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) 2020 statement. Searches were conducted on PubMed/MEDLINE, PsycInfo, EMBASE and Cochrane Library from January 2015, when two prior systematic reviews were conducted, until February 2021. Two independent authors reviewed the studies with the Revised Cochrane Collaboration's Risk of Bias tool for Randomised trials.

resultsWe identified 16 RCTs (N = 859) investigating cognitive remediation (CR; k = 6; N = 311), direct current or repetitive magnetic stimulation (k = 3; N = 127), or pharmacological interventions (k = 7; N = 421). CR showed most consistent cognitive benefits, with two trials showing improvements on primary outcomes. Neuromodulatory interventions revealed no clear efficacy. Among pharmacological interventions, modafinil and lurasidone showed early positive results. Sources of bias included small samples, lack of pre-screening for objective cognitive impairment, no primary outcome and no information on allocation sequence masking.

conclusionsEvidence for pro-cognitive treatments in mood disorders is emerging. Recommendations are to increase sample sizes, pre-screen for impairment in targeted domain(s), select one primary outcome, aid transfer to real-world functioning, investigate multimodal interventions and include neuroimaging.

Indexed as

Bipolar DisorderCognitive DysfunctionCognitionHumansLurasidone HydrochlorideMood DisordersLurasidone Hydrochloridebipolar disordercognitive impairmentinterventionISBD Task Forcemajor depressive disorderrandomised controlled trialsrecommendationssystematic review

Identifiers

PMID35174594
PMCPMC9541874
OpenAlexW4213211209

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.